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Nonsteroidal anti-inflammatory drugs (NSAIDs) have long been used to treat pain, fever, and inflammation. However, mounting
evidence shows thatNSAIDs, such as aspirin, have very promising antineoplastic properties.The chemopreventive, antiproliferative
behaviour of NSAIDs has been associated with both their inactivation of cyclooxygenases (COX) and their ability to induce
apoptosis via pathways that are largely COX-independent. In this review, the various proapoptotic pathways induced by
traditional and novel NSAIDs such as phospho-NSAIDs, hydrogen sulfide-releasing NSAIDs and nitric oxide-releasing NSAIDs
in mammalian cell lines are discussed, as well as the proapoptotic effects of NSAIDs on budding yeast which retains the hallmarks
of mammalian apoptosis. The significance of these mechanisms in terms of the role of NSAIDs in effective cancer prevention is
considered.
1. Introduction
In recent years, there has been a growing interest in aspirin
and other nonsteroidal anti-inflammatory drugs (NSAIDs)
because of their promising antineoplastic properties. Epi-
demiological, clinical, and experimental evidence strongly
indicates that NSAIDs exert a significant chemopreventive,
antiproliferative effect on several types of cancer cells (see
Table 1). Much of the research concerning the antineoplastic
effects of NSAIDs has focused on the effect of aspirin in large
bowel cancers, with comparatively fewer studies carried out
on the chemopreventive effects of other NSAIDs [1]. In fact,
aspirin stands as the most widely studied pharmacological
agent for the chemoprevention of colorectal malignancies,
with numerous clinical trials being carried out to examine its
role in the prevention of adenomas, colorectal carcinomas,
and inherited colorectal neoplasias such as the Lynch syn-
drome and familial adenomatous polyposis (FAP) [2]. Such
focus on aspirin may be due, in large part, to the increasingly
high prevalence and social impact of human colorectal cancer
in recent years [2]. It is also due to the simple fact that long-
term aspirin use is already widely practised among patients
for the prevention of cardiovascular events such as thrombo-
sis and neurovascular events such as stroke, thus providing
a convenient opportunity for researchers to study its other
long-term chemopreventive effects. In fact, major findings of
aspirin’s anticancer effects in humans are also derived from
clinical trial data originally compiled for the study of its anti-
thrombotic effects [3, 4]. Aspirin’s affordability and ease of
access, together with its relatively reduced side effects with
respect to other traditional NSAIDs [5], have also helped to
increase its appeal as a potential chemopreventive agent and
target in anticancer studies.
Nevertheless, a considerable number of investigations
have shown that other NSAIDs including sulindac [6–8],
indomethacin [9, 10], ibuprofen [11, 12], naproxen [13],
and diclofenac [14–16] also exhibit significant antineoplastic
behaviour in mammalian cancer cells. Additionally, recent
studies have increasingly focused on the chemopreventive
properties of a new NSAID class referred to as modified
NSAIDs. These are essentially traditional NSAIDs which can
either have nitric oxide- (NO-) donating moieties, hydrogen
sulphide- (H
2
S-) donating moieties, or phosphate moieties
covalently attached to the –COOH site via aromatic or
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aliphatic spacermolecules, as shown in Figure 1.The resulting
modified NSAID classes, known as NO-donating NSAIDs
(NO-NSAIDs), H
2
S-donating NSAIDs (HS-NSAIDs), and
phospho-NSAIDs, respectively, have all been shown to be
far less toxic than their NSAID precursors and several times
more potent in terms of antineoplastic efficacy [17–22].
The exceedingly potent anti-neoplastic properties of novel
NSAID chimeras, which are characterized by their pos-
session of both NO- and H
2
S-donating moieties (see Figure
1), have also begun to attract significant attention [23, 24].
The mechanistic pathways which mediate the anti-neo-
plastic effects of traditional andmodifiedNSAIDs are still not
fully understood. It has been postulated that the antiprolifer-
ative effect of NSAIDs on malignant cells involves the inhibi-
tion of proinflammatory COX activity [25] and prostaglandin
formation [26]. However, additional evidence shows that
NSAIDs can induce apoptotic cell death in tumour cells [27]
via pathways that are largely independent of COX [6, 28,
29].The elucidation of apoptotic mechanisms underlying the
chemopreventive effect of NSAIDs has long been the focus of
intense research using a broad range of experimental models,
including whole mammalian specimens, human cancer cell
lines, and Saccharomyces cerevisiae cells.
1.1. Yeast Cells as a Model for the Study of the Proapoptotic
Effects of NSAIDs. Yeast cell species, such as Saccharomyces
cerevisiae, are among the preferred and extensively used
experimental models for the study of programmed cell
death associated with ageing, disease, and cancers in living
organisms. This is partly because yeast cells retain many core
elements of mammalian cell processes such as apoptosis [30].
Additionally, these primitive eukaryotes have a number of
important advantages over complex mammalian cell models.
Yeast cells are relatively inexpensive and easy to handle, with
a relatively brief lifespan that permits rapid generation of
experimental results in a shorter span of time. Moreover, the
yeast cell genome is verywell characterised and relatively easy
to manipulate, allowing for the ready availability of yeast
mutant strains for experimental studies. Overall, these fea-
tures collectively account for the successful use of budding
yeast as a model organism for the study of molecular path-
ways underlying mammalian pathologies such as cancer.
These same advantages of the yeast cell experimental
model also account for its wide use in the study of proapop-
totic pathways underlying the anti-neoplastic behaviour of
antitumour drugs such as paclitaxel, bleomycin, valproate,
and arsenic [31]. These compounds have been studied exten-
sively in yeast cells in an effort to improve anticancer
strategies in human patients. Likewise, S. cerevisiae budding
yeast cells have also been used to study the growth inhibitory,
proapoptotic effects of NSAIDs such as aspirin [32] and
diclofenac [33].
The study of the proapoptotic effects of NSAIDs in yeast
models is still a relatively new concept, with far fewer studies
having been carried out in yeast with respect to mammalian
cells. Regardless, evidence acquired thus far from yeast
studies of NSAIDs such as aspirin has already yielded valu-
able insights into their proapoptotic behaviour, highlighting
Table 1: Human cancer cell targets of the proapoptotic effects of
prominent traditional and modified NSAIDs.
NSAID type Target cell type [references]
Traditional NSAIDs
Aspirin
Colon cancer cells [34–36], leukaemia cells
[37, 38], cervical cancer cells [39, 40],
gastric cancer cells [41–44], hepatocellular
carcinoma cells [45, 46], endometrial
cancer cells [29], neuroblastoma cells [47]
Indomethacin Colon cancer cells [7, 35], Gastric cancercells [44], Endometrial cancer cells [29]
Sulindac
Colon cancer cells [6, 7, 48, 49], prostate
cancer cells [48], hepatocellular carcinoma
cells [8], lung cancer cells [50]
Ibuprofen Colon cancer cells [51]
Diclofenac Neuroblastoma cells [15], melanoma cells[16]
Tolfenamic Acid Prostate cancer cells [52]
Modified NSAIDs
NO-Aspirin Pancreatic cancer cells [53], colon cancercells [17, 54–58]
NO-sulindac Colon cancer cells [17], melanoma cells[59]
NO-ibuprofen Colon cancer cells [17]
NOSH-aspirin Colon cancer cells [24]
Phosphoaspirin Colon [19, 21, 56], pancreatic [21], andbreast [21] cancer cells
Phosphosulindac Colon, pancreatic, and breast cancer cells[21]
HS-aspirin Colon cancer cells [22], breast cancer cells[60]
HS-ibuprofen Colon cancer cells [22]
HS-naproxen Colon cancer cells [22]
HS-sulindac Colon cancer cells [22]
factorswhich play key roles inNSAID-induced death (such as
reactive oxygen species (ROS) and mitochondrial dysfunc-
tion). In fact, compelling evidence has shown that S. cerevisiae
cells constitute a powerful model for the screening and devel-
opment of NSAIDs and other proapoptotic drugs designed
for use in human cancer patients, overcoming the problem of
cell specificity in the design of antitumour compounds [31],
whilst also serving as an inexpensivemodel to initially test the
effect of antitumour drugs before assaying them in more rel-
evant mammalian systems.Therefore, yeast cells clearly serve
an important role as a complementary experimentalmodel to
mammalian cells in the study and elucidation of NSAID-
induced mechanisms of apoptosis.
In this review, important biomolecular pathways trig-
gered by traditional and novel NSAIDs which lead to the
induction of apoptosis in mammalian cell lines and in S. cere-
visiae yeast cells will be discussed. The significance of these
proapoptotic mechanisms, in the context of the role NSAIDs
may play in the design of more effective cancer prevention
strategies, is also considered.
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Figure 1: Chemical structures of modified NSAIDs and their traditional NSAID precursors. Phosphosulindac, which exemplifies phospho-
NSAIDs, consists of the sulindac molecule linked at the –COOH site to a phosphate group via an aliphatic spacer molecule (both shown in
green). In the HS-NSAID known as HS-ibuprofen, an aromatic spacer molecule links an H
2
S-releasing dithiolethione group (both shown in
red) to the ibuprofen structure. Similarly, the NO-NSAID NO-aspirin is composed of an NO-releasing-NO
2
group and an aromatic spacer
molecule (both shown in blue) which is linked to the –COOH group of aspirin. Finally, the modified NSAID chimera known as NOSH-
aspirin is characterized by the aspirin structure linked via two separate spacer molecules to both a H
2
S-releasing moiety (shown in red) and
an NO-releasing moiety (shown in blue).
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2. NSAID-Induced COX Inhibition and
Apoptotic Cell Death
The cyclooxygenase isoforms COX-1 and COX-2, both of
which are key requirements for the synthesis of prostaglan-
dins in mammalian cells, constitute the best defined phar-
macological targets of NSAIDs such as aspirin [61, 62]. Thus,
it has long been postulated that the chemopreventive effect
of NSAIDs is mediated by their ability to inactivate COX-
enzymes, causing inhibition of prostaglandin synthesis and
consequent suppression of both tissue inflammation and
cell proliferation, two conditions heavily associated with
tumour formation [25]. In fact, both prostaglandins andCOX
enzymes, particularly COX-2, are implicated in tumorigene-
sis [1, 2, 63, 64] and have been observed in high quantities in
several types of human tumours, including colorectal carci-
nomas [65–69]. Moreover, prostaglandins such as PGE
2
are
known to promote angiogenesis, alter cellular immunity,
increase both proliferation and invasiveness of cells, and
enhance cellular resistance to apoptosis [2, 68, 70].
It has been shown that deletion of receptors for PGE
2
confers resistance to both polyp and cancer formation [71].
Similarly, disruption of COX-2 activity was found to reduce
the incidence of polyp [72, 73] and aberrant crypt foci
formation [74] in the intestines of rodent models. Inhibition
of COX-2 has also been shown to be effective in preventing
the formation of human colorectal adenomas [75, 76] and
oesophageal squamous cell carcinoma [64]. Thus, inhibition
of COX-2-dependent prostaglandin synthesis is thought to
mediate, at least in part, the tumour-suppressive, antiprolif-
erative effects of NSAIDs such as the suppression of angio-
genesis and the induced lowering of resistance to apoptosis.
In fact, inhibition of invasive tumour formation in NSAID-
treatedmousemodels has been associatedwith decreased cel-
lular levels of PGE
2
[26].
The anti-neoplastic behaviour of NSAIDs is also associ-
ated with their ability to actively induce apoptosis in malig-
nant cells. However, the means by which COX-2 inhibition
could possibly mediate NSAID-induced cancer cell apoptosis
has long been the subject of debate [77, 78]. As such,
there is no clear evidence implicating direct involvement of
prostaglandins in NSAID-induced apoptosis, which suggests
that prostaglandins do not directly mediate NSAID-induced
death [77–79]. In fact, studies have indicated that aspirin-
induced apoptosis in mouse [80] and human [81] cancer cells
can occur independently of prostaglandin inhibition. Sim-
ilarly, Chan and coworkers [7] demonstrated that apopto-
sis induced by sulindac and indomethacin in mammalian
HCT116 and SW480 colon cancer cell lines did not depend on
prostaglandin depletion since supplementation of these same
cells with prostaglandins failed to protect them from apopto-
sis. However, this same study did present evidence of COX-2-
dependent apoptosis induced by these NSAIDs. The authors
suggested that cellular accumulation of the prostaglandin
precursor arachidonic acid, brought about by the NSAID-
induced inhibition of COX-2, caused cancer cell apopto-
sis by stimulating sphingomyelinase-mediated synthesis of
ceramide [7], which is a proapoptotic molecule [82]. Arachi-
donic acid accumulation in cancer cells also induces ROS
accumulation [83], mitochondrial permeability transition,
and cytochrome c release [84], all of which lead to apoptotic
cell death.
3. COX-Independent NSAID-Induced
Apoptotic Cell Death
The proapoptotic effects underlying the chemopreventive
potential of NSAIDs cannot be accounted for by COX
inhibition alone. Firstly, NSAIDs have been shown to inhibit
proliferation and induce apoptosis in malignant cell lines
which do not express either COX-1 or COX-2, as observed
in cyclooxygenase-null mouse embryo fibroblasts [85] and
human colon cancer cells [28, 81, 86]. Furthermore, NSAID
compounds which cannot inactivate COX-2, such as sulindac
sulfone, a metabolite of sulindac [87], have been shown to
induce apoptosis of gastric tumour cells [88] and inhibit colon
tumour formation in rodents [89, 90]. Additionally, NSAID
concentrations required to induce apoptosis in cancer cells
have often been found to be significantly higher than that
required to inhibit COX-2, suggesting the presence of alterna-
tive cellular targets of NSAIDs [27, 37, 77, 91]. Indeed, numer-
ous studies have shown that NSAID-induced apoptosis in
mammalian tumour cells can be mediated by several largely
COX-independent metabolic pathways, the most prominent
of which are presented in the following discussion.
3.1. Activation of Caspases and Modulation of Bcl-2 Proteins.
NSAIDs can mediate apoptosis by inducing the activation
of caspases, a family of proapoptotic cysteine proteinase
enzymes which typically exist as latent zymogens in cells.
Activation of these proteins by proapoptotic signals initiates
a caspase cascade whereby initiator caspases specifically acti-
vate other executioner-type caspases. The latter then degrade
multiple cellular components so that cells begin to acquire the
morphological and biochemical features of apoptosis [92].
Bellosillo and coworkers [37] were among the first to present
evidence of NSAID-induced caspase activation.They showed
that B-chronic lymphocytic leukemia (B-CLL) cells treated
with high doses of aspirin underwent apoptosis characterised
by DNA fragmentation and degradation of poly (ADP-
ribose) polymerase (PARP), which is a caspase substrate.
The apoptotic phenotype was inhibited by application of the
pan-caspase inhibitor Z-VAD-FMK, thus confirming the
involvement of caspases in aspirin-induced B-cell apoptosis.
Similarly, Castan˜o and coworkers [34] affirmed caspase
involvement in aspirin-induced apoptosis of HT-29 human
colon adenocarcinoma cells. However, contrary to its effect
in B cells, aspirin did not induce PARP degradation in HT-29
cells. This observation is probably one of the earliest to sug-
gest that NSAID-induced activation of caspases can occur via
different pathways.
Indeed, it has since been shown that NSAIDs activate cas-
pases both via the mitochondrial-mediated (intrinsic) path-
way, which involves mitochondrial cytochrome c release and
subsequent activation of caspase 9, and via the death-receptor
mediated (extrinsic) pathway, which involves the activation
of caspase 8 [41]. Proapoptotic NSAID-induced activation
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of caspases, mediated by the early release of mitochondrial
cytochrome c in mammalian cancer cells, has clearly been
demonstrated by studies such as that of Pique´ et al. [38]. The
authors reported that cytochrome c release preceded both the
disruption of the mitochondrial membrane potential (ΔΨ𝑚)
and the activation of caspases. The latter observation was
confirmed by Zimmermann and coworkers [39] who in turn
showed that, in aspirin-induced apoptosis of human cancer
cells, the release of mitochondrial cytochrome c was itself
triggered by translocation of proapoptotic Bax protein to the
mitochondria. Conversely, overexpression of antiapoptotic
Bcl-2 protein inhibited both cytochrome c release and apop-
tosis of aspirin-treated cancer cells. Furthermore, deletion of
apoptotic protease-activating factor-1 (APAF-1), a cytosolic
molecule which mediates caspase 9 activation after binding
to mitochondrial cytochrome c, rendered cells resistant to
aspirin-induced apoptosis. These observations indicate that
cytochrome c release is a critical mediatory mechanism of
apoptotic cell death induced by NSAIDs [39]. In fact, it has
also been shown that aspirin-induced apoptosis of S. cere-
visiae cells deficient in manganese superoxide dismutase
(MnSOD) and cultivated in nonfermentable ethanolmedium
is preceded by the early release of cytochrome c, followed by
a drastic fall in ΔΨ𝑚 [93].
Extrinsic activation of caspase 8 is also an important
mediator of NSAID-induced cancer cell apoptosis [42, 48].
Activated caspase 8 can initiate apoptosis by activating down-
stream caspases or by cleaving the BH3-domain only protein
Bid. Truncated Bid (tBid) can translocate to themitochondria
to trigger cytochrome c release [94, 95] and can also activate
Bax [96]. Indeed, aspirin-induced apoptosis of AGS gastric
cancer cells was marked by activation of caspase 8 and Bid
cleavage, along with the mitochondrial translocation of Bax,
activation of downstream caspases, and cleavage of PARP.
Specific inhibition of caspase 8 abrogated cleavage of both Bid
and PARP and prevented aspirin-inducedAGS cell apoptosis,
thus implicating extrinsic caspase activation in the initiation
of aspirin-induced apoptosis [42]. However, in this same
study, the release of cytochrome c and activation of caspase
9 were also observed, thus suggesting the involvement even
of mitochondrial-mediated caspase activation. In fact several
other studies have since shown that the chemopreventive
apoptotic effect of aspirin [41, 43, 45, 46] and modified
NSAIDs such as NO-aspirin [97] and phosphosulindac [20]
onmammalian cancer cells may involve the initiation of both
intrinsic and extrinsic caspase activation pathways, which
operate in parallel to one another.
The ability of NSAIDs to activate caspases largely explains
the profound influence they have on Bcl-2 proteins such
as Bax, Bid, and Bcl-2 [42, 43], the expression and cellular
distribution of which can be greatly altered by NSAIDs to
mediate apoptosis in cancer cells. NSAIDs such as aspirin
and indomethacin have long been shown to induce cancer
cell apoptosis by upregulating the expression of proapoptotic
Bcl-2 proteins, such as Bax and Bak, and by downregulating
expression of anti-apoptotic Bcl-2 proteins such as Bcl-2 and
Bcl-XL [29, 44]. More recent work has shown that NSAID-
induced downregulation of Bcl-XL can be induced in part by
proteasome-mediated protein degradation [98].
NSAID-induced intrinsic and extrinsic activation of cas-
pases, along with modulation of Bcl-2 protein expression, all
seem to converge at the mitochondria. Here, these pathways
induce events such as the release of cytochrome c and other
proapoptotic molecules, including SMAC/Diablo, from the
mitochondria [43], which irreversibly commit cells to the full
apoptotic phenotype. Thus mitochondria clearly constitute
a very important target of NSAID-induced apoptosis, as
indicated by the many studies associating NSAID-induced
apoptosis of mammalian cells with mitochondrial dysfunc-
tion, such as uncoupling of oxidative phosphorylation [99],
inducedmitochondrial permeability transition [100, 101], and
inactivation of mitochondrial enzymes such as aconitase and
respiratory chain proteins [45].
Likewise, it has been shown that the mitochondria of S.
cerevisiae cells constitute a critical target of NSAIDs such as
aspirin [32], the proapoptotic effects of which were shown to
be associated with inhibition of the electron transport chain
[93]. Similarly, Van Leeuwen and coworkers [33] observed
that growth inhibition and apoptosis of S. cerevisiae cells
caused by treatment with the NSAID diclofenac were due to
mitochondrial dysfunctional events involving the inhibition
of the electron transport chain.The fact that yeast cells, which
are primitive eukaryotes, share a common mitochondrial
target of NSAIDs with mammalian cells is highly significant,
because it suggests that mitochondria constitute a unifying,
dominant target of NSAID-induced apoptosis in all mam-
malian cancer cell types. This may certainly help inform
the design of more effective NSAIDs for chemopreventive
purposes and illustrates the important contribution of yeast
cells as a complementary experimental model for the study of
NSAID-induced apoptotic mechanisms.
3.2. Depletion of Polyamines. Polyamines such as spermine,
spermidine, and putrescine are abundant polycations found
in all eukaryotic cells and play an essential role in cellular
development and proliferation [102]. High polyamine levels
are in fact associated with the induction of cell proliferation
[103, 104], whilst lowered polyamine levels have been found
to promote cell growth inhibition [105] and apoptosis [106].
Hence, it is no surprise that the polyamine content of cancer
cells tends to be significantly higher than that of normal cells
[102], thus representing a potential target of anti-neoplastic
agents such as NSAIDs, a number of which have been shown
tomediate their chemopreventive effect by promoting the cat-
abolic degradation of polyamines in cancer cells [35, 49, 107].
This takes place by virtue of the general ability of NSAIDs
to modulate cellular polyamine metabolism, which is reg-
ulated by the biosynthetic enzyme ornithine decarboxylase
(ODC) and the catabolic polyamine-acetylating enzyme
spermidine/spermine N1-acetyltransferase (SSAT) [49, 107].
For instance, indomethacin-induced growth inhibition of
human colon cancer cells has been shown to be associated
with downregulation of ODC activity and upregulation of
SSAT activity, which concurrently impair the synthesis of
polyamines and increase the rate at which they are degraded.
The consequent depletion of cellular polyamines was accom-
panied by apoptotic cell death [35]. Other traditionalNSAIDs
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such as aspirin [108], sulindac sulfone [49], and ibuprofen
[107] mainly induce the enhanced degradation and export
of polyamines by upregulating gene expression of SSAT in
cancer cells, resulting in reduced proliferation and increased
apoptosis.This is also true of modifiedNSAIDs such as phos-
phosulindac [20], the antiproliferative proapoptotic effect
of which can, like its NSAID precursor sulindac [109], be
enhanced even further by concurrent treatment of cells with
ODC inhibitors such as difluoromethylornithine (DFMO)
[20, 110, 111]. Both DFMO and phosphosulindac act syner-
gistically to enhance the depletion of polyamines in colon
cancer cells, strongly inhibiting their proliferation and greatly
enhancing apoptosis [20].
3.3. Modulation of NF-𝜅B Activity. Nuclear factor kappa B
(NF-𝜅B) is a ubiquitous cellular transcription factor which
regulates the expression of genes associated with inflam-
mation, immune responses, cell growth, differentiation, and
apoptosis. Composed of p65 (RelA) and p50 polypeptides,
this complex transcription factor is sequestered in an inactive,
heterodimeric form within the cell cytoplasm by I kappa
B alpha (I𝜅B𝛼) or beta (I𝜅B𝛽) inhibitor proteins [112, 113].
Stimulation by appropriate signals (such as proinflammatory
cytokines including tumour necrosis factor (TNF)) triggers
the IK𝛼 or IK𝛽 kinase- (IKK-) mediated phosphorylation
of I𝜅B proteins, which consequently undergo ubiquitin-
dependent proteasomal degradation. This permits transloca-
tion of NF-𝜅Bmolecules to the nucleus, where they then bind
to and promote the transcription of numerous target genes
bearing a 𝜅B-binding motif [79, 113, 114].
The constitutive activation of NF-𝜅B is a hallmark of sev-
eral types of cancers [115–117] and is heavily associated with
cancer cell resistance to cytotoxic agents, due in part to its
induced upregulation of anti-apoptotic proteins [118]. Thus,
NF-𝜅B constitutes yet another potential target of chemother-
apeutic agents such as NSAIDs, which can modulate NF-𝜅B
signalling in cancer cells to promote the onset of apoptosis
[36, 54, 60, 107, 111, 114, 119].
Traditional NSAIDs such as aspirin have been reported
to inhibit NF-𝜅B activation by preventing the degradation of
I𝜅B [119]. Aspirin can inhibit TNF-induced I𝜅B𝛼 degrada-
tion [120] by modulation of p38 mitogen-activated protein
(MAP) kinase pathways [121] and by disrupting the ubiquitin-
dependent proteasomal pathway, of which I𝜅B𝛼 is a substrate
[47]. Aspirin can also block I𝜅B𝛽 degradation through
competitive inhibition of IKK𝛽-ATPmolecular binding, thus
facilitating selective inhibition of IKKkinase (IKK𝛽) [114]. All
these mechanisms prevent NF-𝜅B activation and subsequent
transcription of anti-apoptotic proteins. It has also been
shown that the NSAID sulindac specifically inhibits IKK𝛽
activity and NF-𝜅B activation in cancer cells, thus promoting
apoptosis [122]. Likewise, the growth inhibitory effect of
NSAIDs such as ibuprofen [51], indomethacin, and etori-
coxib, a recently developed COX-2 inhibitor [117], is associ-
ated with their inhibition of NF-𝜅B signalling in cancer cells.
The growth inhibitory effect mediated by modified
NSAIDs such as NO-NSAIDs, on various cancer cell lines,
also involves the modulation of NF-𝜅B signalling [54, 55].
The growth inhibitory effect of NO-aspirin, associated with
its ability to reduce proliferation and enhance apoptosis of
cancer cells, was shown to be significantly correlated to its
profound inhibition of the NF-𝜅B signalling pathway, the
occurrence of which was suggested to be due to inhibition
of NF-𝜅B binding to DNA in the nucleus [55]. Sun and Rigas
[56] went on to demonstrate that proapoptotic inhibition of
NF-𝜅B signalling in human colon cancer cell lines, treated
with NO-aspirin, stemmed from the latter’s induced gener-
ation of reactive oxygen and nitrogen species (RONS), which
may have interacted directly or indirectly (via the redox-
sensitive thioredoxin (TRX) system) with NF-𝜅B, impairing
its ability to bind to recognition DNA sequences in the
nucleus. This is highly conceivable given that NF-𝜅B tran-
scriptional activity is sensitive to redox changes [123]. In fact,
it has since been shown that structurally diverse NO-NSAIDs
such as NO-aspirin and NO-naproxen can suppress NF-𝜅B
signalling in cells via S-nitrosylation of the NF-𝜅B transcrip-
tion factor. This redox-signalling mechanism is mediated by
the released NO group which, on binding to the p65 mono-
mer of NF-𝜅B, impairs the transcription factor’s ability to
bind to DNA [57]. The redox-induced inhibition of NF-
𝜅B signalling is thought also to partly mediate the growth
inhibitory effect (including apoptosis, cell cycle arrest, and
inhibition of proliferation) of phospho-NSAIDs [19, 21, 111]
and HS-NSAIDs in cancer cells [60].
Intriguingly, the effect of NSAIDs on NF-𝜅B activity
seems to be cell-type specific, since aspirin-induced apoptosis
of HCT 116 colon cancer cells was shown to be mediated by
the activation of NF-𝜅B signalling, rather than its inhibition
[36]. Additionally, Din and coworkers [124] observed that
aspirin-induced I𝜅B𝛼 degradation, activation of NF-𝜅B sig-
nalling, and apoptosis took place in colorectal cancer cells but
not in other malignant cell types. Loss of cellular I𝜅B𝛼, which
is indicative of NF-𝜅B activation, has also been reported
in aspirin-induced apoptosis of both immortalised human
endothelial cells [125] and animalmodels of human colorectal
cancer [126]. Likewise, Babbar and coworkers [107] observed
that aspirin caused the activation of NF-𝜅B signalling in
Caco-2 colon cancer cells, suggesting even that this event
was responsible for the upregulation of SSAT expression and
polyamine depletion which led to apoptosis. Besides aspirin,
other traditional NSAIDs such as diclofenac have also been
reported to induce activation of NF-𝜅B signalling as a means
to attenuate cancer cell proliferation and promote apoptosis
[127]. It has been argued that the varying effects ofNF-𝜅Bmay
be due to the specificity by which this transcription factor
binds to DNA and activates target genes. Such specificity is
in turn dependent on the dimeric composition of the NF-
𝜅B complex and on the transcriptional cofactors that it has
recruited, both ofwhich can vary depending on the kinetics of
induction [128]. Therefore, different stimuli or even the same
stimulus exerted under different conditions can induce dif-
ferent NF-𝜅B complexes and different downstream responses
[36, 107].
3.4. Modulation of MAP-Kinase Activity. Mitogen activated
protein (MAP) kinases are serine/threonine-specific proteins
which respond to extracellular stimuli and regulate various
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cellular pathways including mitosis, cell proliferation, sur-
vival and death [129]. The three principal MAP kinase
subgroups include the extracellular signal-regulated kinases
ERK1/2 (p42/p44), c-Jun N-terminal kinases/stress-activated
protein kinases (JNKs/SAPKs), and the p38 MAP kinases
[121]. NSAIDs such as aspirin and its metabolite salicylate
have long been shown to modulate MAP kinase signalling
in mammalian cells [130, 131]. This is exemplified by the
salicylate-induced activation of p38MAP kinase signalling in
FS-4 fibroblasts, which induced apoptosis [130] via a pathway
involving theNSAID-induced inhibition of I𝜅B𝛼degradation
and NF-𝜅B signalling [121]. Based on these observations, the
authors concluded that apoptotic cell death induced by p38
MAP kinase activation played an important role inmediating
the anti-neoplastic effects of NSAIDs. The important medi-
atory role of MAP kinase modulation in the context of the
anti-neoplastic effects of NSAIDs was further highlighted by
Jones and coworkers [132], who demonstrated that NSAID-
induced inhibition of angiogenesis involved the disruption
of ERK1/2 kinase signalling, a typically prosurvival path-
way [133]. Additionally, inhibition of ERK1/2 signalling was
shown to be the mechanism by which aspirin sensitises
human cervical cancer cells to apoptosis induced by tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL)
[40]. Modulation of MAP kinases has also been implicated
in the suppressive effect of certain NSAIDs such as aspirin
upon the factor activator protein (AP-1), a downstream target
of MAP kinases which is critical for inducing neoplasia and
activation of genes associated with inflammation and infec-
tion [134].
The modulation of MAP kinases has been shown to be
critical for the growth inhibitory effect of modified NSAIDs
such as NO-aspirin [135]. Aside from its propensity to inhibit
NF-𝜅B signalling, NO-aspirin was shown to induce the
activation (marked by increased phosphorylation) of all three
main MAP kinases in a concentration-dependent manner,
in colon cancer cells. This was caused by the NO-aspirin-
induced generation of RONS and subsequent oxidation of
cellular thioredoxin-1 protein (Trx1p), which facilitated the
proapoptotic autophosphorylation and activation of ASK1, a
protein involved in the MAP kinase cascade and only kept
inactive when attached to reduced Trx1p [56]. The same
authors implicated ASK1-Trx1p cleavage in the activation of
MAP kinase signalling, which in turn partly mediated the
growth inhibitory effect of NO-aspirin, an effect marked
by increased apoptosis and inhibition of cell proliferation.
Likewise, NO-aspirin-induced cell cycle arrest and apoptosis
of pancreatic cancer cells has been shown to occur via ROS-
mediated modulation of all three MAP kinase signalling
pathways and their downstream effector molecules such as
p21 and cyclin D1 [53]. The rapid response of MAP kinases
to the presence of RONS is not surprising given their well-
established redox sensitivity [136]. The modulation of MAP
kinase pathways was also implicated in the chemopreventive
effect of NO-sulindac on UVB-induced melanoma cells [59]
and in phospho-NSAID-mediated, redox-dependent apopto-
sis of colon cancer cells [19, 111].
3.5. Inhibition of Wnt/𝛽-Catenin Signalling. The Wnt sig-
nalling pathway regulates the biosynthesis of 𝛽-catenin,
a protein which is required for cell-to-cell adhesion and
involved in the expression of genes associated with cancer
[137]. Constitutive activation ofWnt/𝛽-catenin signalling has
been implicated in the development of numerous human
malignancies [138–143]. AberrantWnt/𝛽-catenin signalling is
associated with the nuclear accumulation of 𝛽-catenin and
the subsequent activation of the transcription factor known
as T-cell factor (TCF). The resulting 𝛽-catenin/TCF complex
promotes the transcriptional activation of target genes associ-
ated with proliferation, such as cyclin D1 [144, 145], hence the
implicated role of Wnt/𝛽-catenin signalling in human car-
cinogenesis.
The NSAIDs aspirin and indomethacin have been shown
to attenuate Wnt/𝛽-catenin signalling in colorectal cancer
cells, in a dose-dependent manner, by inhibiting the tran-
scription of 𝛽-catenin/TCF-responsive genes. This NSAID-
induced inhibition did not involve cleavage of the 𝛽-cate-
nin/TCF complex but rather the hyperphosphorylation and
consequent stabilization of 𝛽-catenin, presumably caused by
the inactivation of a phosphatase enzyme [146, 147]. Further
studies have since shown that aspirin-mediated downregula-
tion of Wnt/𝛽-catenin/TCF signalling can indeed be medi-
ated by its induced inactivation of protein phosphatase 2A
[148] but also, in part, by the downregulation of upstream
specificity protein (Sp) transcription factors [149]. Other
NSAIDs, such as sulindac, can also mediate the antiprolifera-
tive degradation of 𝛽-catenin in cancer cells partly by protea-
somal degradation and partly by caspase-mediated cleavage
[150], whilst others such as diclofenac have been shown to
suppress Wnt/𝛽-catenin/TCF signalling via the activation of
NF-𝜅B [127].
The downregulation of Wnt/𝛽-catenin/TCF signalling
induced by NSAIDs has been associated with the profound
growth inhibition of various cancer cell types, in a manner
that seems in large part to be due to inhibition of cell prolif-
eration rather than by direct induction of apoptosis [127, 142,
146, 150, 151]. However, the proapoptotic effect of NSAIDs
such as sulindac [152] in colorectal cancer cell lines has been
shown to involve downregulation ofWnt/𝛽-catenin/TCF sig-
nalling. Furthermore,Wnt/𝛽-catenin signallingwas observed
to play a key role in directly mediating the proapoptotic
effect of aspirin in human mesenchymal stem cells [153].
Regardless, the high prevalence of 𝛽-catenin downregulation
reported in studies of NSAID-induced growth inhibition of
cancer cells underlines the importance of this pathway as a
chemopreventive target of NSAIDs.
This is certainly true for modified NSAIDs such as NO-
aspirin, the growth inhibitory effect of which is strongly asso-
ciated with a number of induced cellular events including the
profound concentration-dependent inhibition of 𝛽-catenin
signalling in colon cancer cells [54, 58, 145, 154]. In this
regard, NO-aspirin is far more effective than aspirin in that,
at concentrations far below those required for the inhibi-
tion of cell proliferation, it actually prevented formation of
the 𝛽-catenin/TCF complex, whereas aspirin did not [145].
Moreover, at higher concentrations, NO-aspirin can induce
caspase-3-mediated cleavage of 𝛽-catenin itself, leading to
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a significant decline of cellular 𝛽-catenin levels and loss of
cell-to-cell adhesion amongst colon cancer cells [58].The sig-
nificant downregulation of Wnt/𝛽-catenin signalling, medi-
ated at least in part by caspase-mediated 𝛽-catenin degrada-
tion, has also been implicated in the growth inhibitory effect
of NO-aspirin on leukaemia [97] and breast cancer cell lines
[155]. The same applies for phospho-NSAIDs such as phos-
phosulindac, the growth inhibitory effect of whichwas shown
to involve 𝛽-catenin degradation in breast cancer stem cells
[156].
3.6. Oxidative Stress and Disruption of Redox Balance.
NSAIDs can mediate apoptosis in both malignant cell lines
and budding yeast cells by upregulating the generation of
ROS and by inducing oxidative stress. Indeed, it has been
argued that ROS generationmay constitute a central unifying
mechanism by which the anti-neoplastic effects of NSAIDs
aremediated, given that oxidative stress is coupled withmany
proapoptotic signals such as NF-𝜅B inhibition and MAP
kinase activation [157, 158]. The fact that ROS accumulation
alsomediates NSAID-induced apoptosis in primitive eukary-
otes such as yeast [33] further corroborates this argument.
However, the cellular prooxidant behaviour of NSAIDs has
often been the subject of controversy due to conflicting
reports that NSAIDs such as indomethacin and sulindac [159,
160] scavenge ROS and exert a cytoprotective antioxidant
effect in cells. Likewise, there are numerous reports derived
from in vivo studies of rats showing that NSAIDs such as
aspirin can exert a cytoprotective antioxidant effect associ-
ated with the attenuation of ROS [161, 162] and of lipid perox-
idation [163, 164], alongwith the upregulation of antioxidants
such as reduced glutathione (GSH) [165] and superoxide dis-
mutases (SODs) [166]. It has also been shown that low doses
of aspirin can confer long-term cytoprotective resistance
against H
2
O
2
-induced oxidative stress in S. cerevisiae cells
[167].
Nevertheless, other investigations have clearly shown that
NSAIDs can induce the proapoptotic accumulation of ROS
in both yeast [33] and mammalian cells [157]. For instance,
apoptotic cell death of respiring S. cerevisiae cells cultivated in
the presence of diclofenac was clearly linked to a significant
increase in cellular ROS, as measured by the ROS-sensitive
fluorescent probe 2󸀠,7󸀠-dichlorodihydrofluorescein diacetate
(DCDHF-DA) [33]. Similarly, indomethacin-induced apop-
tosis of gastric epithelial cells, which was abrogated after
treatment with antioxidants such as N-acetylcysteine (NAC),
was shown to require the generation of ROS [168], an
event likewise implicated in the proapoptotic depletion of
polyamines induced by indomethacin in colorectal cancer
cells [35]. Additionally, Chan and coworkers [7] showed
that human colorectal cancer cell apoptosis induced by both
indomethacin and sulindac was marked by the accumulation
of arachidonic acid, an event which is itself heavily associated
with the accumulation of cellular ROS [83, 169].The accumu-
lation of ROS was also shown to be a critical inducer of mito-
chondrial cytochrome c release, disruption of ΔΨ
𝑚
, caspase
activation, and apoptosis in salicylate-treated mammalian
tumour cells [170]. Additionally, the NSAID sulindac and
its metabolites have been shown to enhance the antitumour
effect of the proteasome-inhibitor bortezomib, primarily
through the synergistic generation of ROS [171]. It has been
suggested that conflicting reports of NSAID redox behaviour
in eukaryotic cells might simply be due to differences in the
timing of measurements of ROS and antioxidant changes
in experimental setups, given that cellular antioxidant levels
are naturally expected to increase in subsequent response to
elevated ROS [157].
The molecular mechanisms underlying NSAID-induced
proapoptotic generation of ROS in mammalian and yeast
cells have not yet been fully elucidated. However, it is well
known that mitochondria, a major source of cellular ROS
[172] and a central component of the apoptotic machinery,
are profoundly affected by NSAIDs in both yeast [33, 93]
and mammalian cells [99, 101]. For example, the aspirin
metabolite salicylate has been shown to inhibit the mito-
chondrial electron transport chain in mammalian cells by
interacting with an Fe-S cluster of Complex I, through its o-
hydroxyl group.This was found to induce ROS accumulation
and oxidative stress, which in turn caused proapoptotic
events such as mitochondrial permeability transition and
cytochrome c release [173]. Likewise, aspirin-induced cell
cycle arrest and apoptosis of HepG2 hepatoma cells were
shown to be induced by ROS accumulation and increased
oxidative stress, accompanied by severe mitochondrial dys-
function such as the inactivation of electron transport chain
proteins and aconitase [45]. Van Leeuwen et al. [33] observed
that reduced cell growth and viability of S. cerevisiae yeast
cells treated with diclofenac are due to mitochondrial dys-
function associated with the inhibition of electron transport
chain subunit proteins Rip1p (of Complex III) and Cox9p
(of Complex IV). This caused inhibition of cell respiration
and subsequent ROS production, resulting in cell death.
Inhibition of cellular respiration induced by aspirin was
also observed in MnSOD-deficient yeast cells cultivated in
ethanol medium [93], and recent studies in our laboratory
have established the aspirin-induced proapoptotic generation
of mitochondrial superoxide radicals in these cells (unpub-
lished work).
It has been shown that the proapoptotic induction of
oxidative stress induced byNSAIDs such as aspirin is strongly
associatedwith themodulation of cellular redox homeostasis.
This is exemplified by the observed increase of aspirin-
induced apoptosis in HepG2 cells with GSH depletion and
compromised redox balance [174]. In addition to this, studies
in S. cerevisiae yeast cells have shown that aspirin-treated
MnSOD-deficient yeast cells grown in ethanol medium
experienced a very significant decrease in cellular reducing
power with respect to wildtype cells, as measured by the
NADPH/NADP+ concentration ratio.This was accompanied
by a significant decrease of the GSH/GSSG concentration
ratio, owing to a buildup of GSSG, prior to cell death [175].
The induction of oxidative stress mediated by disruption
of cellular redox balance is also central to the apoptotic effect
of modified NSAIDs in cancer cells [53, 56, 58, 158]. For
instance, oxidative stress induced by NO-aspirin in colon
cancer cells was shown to be mediated by the depletion of
cellular GSH, caused by the latter’s associationwith the spacer
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component of NO-aspirin and subsequent formation of a
GSH conjugate. The resulting redox imbalance then initi-
ated a number of downstream proapoptotic pathways such
as 𝛽-catenin cleavage, inhibition of Wnt signaling, and
mitochondrial-mediated activation of caspases [58]. Sun and
Rigas [56] further demonstrated that redox-induced apopto-
sis of colorectal cancer cells treated with NO-aspirin involved
the generation of RONS, the growth inhibitory effect of which
was mediated by oxidative alteration and impairment of the
thioredoxin redox system. Oxidised thioredoxin-1 induced
MAP kinase activation and NF-𝜅B inhibition, both of which
are criticalmediatory pathways ofNO-aspirin-induced apop-
tosis [55, 135].
Oxidative stress, marked by RONS accumulation and
redox imbalance associated with the suppression of GSH
and increased oxidation of Trx-1, also plays a central role in
apoptosis induced by phospho-NSAIDs [19–21, 56, 110, 111].
Like NO-NSAIDs, the strong prooxidant effect exerted by
phospho-NSAIDs is reported to set in motion a pleiotropic
cascade of redox-sensitive signalling events including acti-
vation of MAP kinases and inhibition of NF-𝜅B signalling
[19, 21, 56] along with the depletion of cellular polyamines,
at least in the case of phosphosulindac [20, 110, 111]. The
collective initiation of all these antiproliferative, proapoptotic
pathways accounts for the very potent growth-inhibitory
effects of phospho-NSAIDs, with respect to their traditional
NSAID precursors [111]. Likewise, recent studies have shown
that both apoptosis and cell cycle arrest of cancer cells treated
with HS-NSAIDs, such as HS-aspirin, are induced as a result
of oxidative stress and redox imbalance [60].
3.7. Other NSAID-Induced Proapoptotic Pathways. Further
mechanisms by which NSAIDs can promote apoptosis in
malignant cells include the induced depletion of survivin,
an inhibitor of apoptosis protein which regulates the cell
cycle and apoptosis in eukaryotic cells. Survivin expression
in cancers tends to be very high and is in fact associated with
tumour cell chemoresistance, making it an attractive target
of antineoplastic treatments [176], including NSAIDs. Lu and
coworkers [177] showed that aspirin caused significant and
targeted depletion of survivin in breast cancer cells by upreg-
ulating its proteasomal degradation, consequently sensitizing
the tumour cells to TRAIL-induced apoptosis. Moreover,
aspirin acted synergistically with TRAIL to promote apop-
tosis of the breast tumour cells. Similarly it has been shown
that cell cycle arrest and apoptotic cell death induced by the
NSAIDs ibuprofen [51] and tolfenamic acid [52] in human
colon and prostate cancer cells, respectively, are accompanied
by significant depletion of survivin levels.
Another COX-independent proapoptotic pathway in-
duced by NSAIDs is the impairment of proteasome func-
tion, as demonstrated by Dikshit and co-workers [47], who
observed a time- and dose-dependent decline of proteasomal
activity in neuroblastoma cells treated with aspirin. Accom-
panied by the accumulation of ubiquitylated proteins and
profound mitochondrial abnormalities, the aspirin-induced
impairment of proteasomal function was shown to activate
the intrinsic apoptotic pathway, marked by a release of cyto-
chrome c and the activation of caspase 9.
Finally, NSAIDs such as sulindac have been reported to
induce sensitization of cancer cells to mda7/IL24-mediated
apoptosis.Themda7 gene, also known as IL24, is of the inter-
leukin (IL) 10 family of cytokines [178, 179]. Ectopic expres-
sion of mda7 is known to exert a potent tumour-suppressive
effect against a variety of human cancer cells, with little to no
effect on normal cells [180–182]. Furthermore, intratumoural
administration of adenoviral vectors which express mda7
(Ad-mda7) has been shown to exhibit antitumour and antian-
giogenic activity in human lung tumour xenografts [183].
Also, Oida and coworkers [50] demonstrated that Ad-mda7-
mediated growth inhibition and apoptosis of human lung
cancer cells was greatly enhanced by concurrent adminis-
tration of sulindac, which increased the half-life of MDA7
protein in the cells. This resulted in the increased expression
ofMDA7protein and of its proapoptotic downstream effector
proteins including p38MAPK, caspase-9, and caspase-3, con-
sequently sensitizing the lung cancer cells to apoptosis.There-
fore, sulindac essentially altered MDA7 protein turnover in
lung cancer cells in such a way as to promote apoptotic cell
death [50].
4. Concluding Remarks
Ongoing investigations of proapoptotic mechanisms under-
lying the promising anti-neoplastic properties of NSAIDs
such as aspirin remain a top research priority, since an
improved understanding of such pathways will help to
enhance current anticancer drug treatments [2]. What is cer-
tain thus far is that NSAIDs generally exert a dose-dependent
pleiotropic effect on cancer cells (see Figure 2), initiating
a very complex cascade of signalling events which collec-
tively induce apoptosis. Although much more remains to be
elucidated, there is also mounting evidence which suggests
that NSAID-induced signalling events associated with the
induction of oxidative stress, such as mitochondrial dys-
function and altered redox signalling, may be the dominant
pathways underlying all other proapoptotic effects induced by
NSAIDs in cancer cells [184].
Consistent with the growing number of mammalian cell
studies implicating oxidative stress as the dominant pathway
of NSAID-induced growth inhibition [185], the proapoptotic
effects of NSAIDs in yeast cells are likewise associatedmainly
with mitochondrial dysfunction, ROS generation, and redox
imbalance. In particular, yeast cell studies have highlighted
the pivotal importance of mitochondrial MnSOD as a cyto-
protective defence against NSAIDs such as aspirin [32]. This
implies that specific, targeted modulation of mitochondrial
MnSOD can be exploited to enhance NSAID-induced oxida-
tive stress and apoptosis in malignant mammalian cells.
It is currently hypothesised that cancer cells constantly
experiencemuch higher levels of oxidative stress with respect
to normal cells, due to their increased metabolic rate [186].
Because of this, cancer cells are more reliant on antioxidant
enzymes such as MnSOD and are thus believed to be far
more sensitive to perturbations in redox balance compared to
normal cells [16]. In fact, it has been shown that silencing of
MnSOD, using anti-senseMnSOD antibodies, amplifies ROS
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Figure 2:Themajor proapoptotic pathways induced byNSAIDs. Both traditional andmodifiedNSAIDs have been shown to induce apoptosis
in eukaryotic cells by initiating mechanisms which are largely independent of COX inhibition (shown in blue), with the exception being the
COX-2-dependent accumulation of arachidonic acid and subsequent synthesis of ceramide induced by sulindac and indomethacin (shown in
green). ImportantCOX-independent proapoptotic pathways induced byNSAIDs include caspase activation andmodulation of Bcl-2 proteins,
depletion of polyamines, modulation of NF-𝜅B signalling and of MAP kinase activity, inhibition of Wnt/𝛽-catenin signalling, inhibition
of proteasomal function, depletion of survivin, increased expression of mda7/IL24 and also oxidative stress associated with mitochondrial
dysfunction, ROS accumulation and the disruption of cellular redox balance.
accumulation and apoptosis in squamous cell carcinomas
exposed to gamma radiation and anticancer drugs [187].
Moreover, it has recently been shown that silencing of
MnSOD messenger RNA, using small interfering RNA
(siRNA), amplified apoptosis of melanoma cells induced by
the NSAID diclofenac [16]. This same study also demon-
strated that diclofenac-induced accumulation of ROS, deple-
tion of MnSOD expression and activity, and apoptosis were
specific to melanoma cells.
In light of all these lines of evidence compiled through
complementary study of both mammalian and yeast cell
models, the induction of oxidative stress and redox imbalance
induced by NSAIDs, together with the targeted modulation
of mitochondrial MnSOD, merits serious consideration for
future investigations.
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